Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

Intellia Therapeutics reports serious liver enzyme elevation in one patient during Phase 3 trial of nex-z gene editing therapy for ATTR cardiomyopathy; shares drop 26% ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone therapy, comparable to Menarini's Orserdu.

Eli Lil­ly’s ex­per­i­men­tal weight loss drug ap­pears to have set a new bar, help­ing obese pa­tients in a Phase II study lose 24% of their … ...

Ei­sai has slashed 2027 sales pro­jec­tions for its Bio­gen-part­nered Alzheimer’s treat­ment Leqem­bi by rough­ly half.

Unit­ed­Health Group’s Op­tum is shut­ting down its vir­tu­al care busi­ness, End­points News has learned. Known as Op­tum Vir­tu­al Care, the busi­ness pro­vides on­line ur­gent ...

Turn Biotech­nolo­gies, a start­up de­vel­op­ing mR­NA ther­a­pies to wind back the clock on ag­ing cells has ac­quired an ex­per­i­men­tal drug de­liv­ery tech­nol­o­gy from ...

Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a … ...

Eli Lil­ly will pay up to $1.925 bil­lion in cash for weight loss drug­mak­er Ver­sa­nis, mark­ing the Big Phar­ma’s fourth ac­qui­si­tion this sum­mer af­ter deals … ...

As­traZeneca is fur­ther in­vest­ing in Chi­na, open­ing an R&D cen­ter in Bei­jing and ink­ing a pair of ma­jor­ly back­loaded R&D deals with Chi­nese drug de­vel­op­ers … ...

MADRID — When Dai­ichi Sankyo sci­en­tists pushed for­ward with an­ti­body-drug con­ju­gate re­search near­ly a decade ago, the pro­gram had a lot of naysay­ers, even in­side the … ...